Sibannac, Inc.
OperatingBiotech · Phoenix, AZ
Financials
FY2011–FY2021 (no data for FY2017, FY2018, FY2019) · from SEC filings · hover any figure for its sourceFigures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Pre-money — the valuation set before each round’s money came inDotted grey bars are our estimate for rounds that didn't state one: the round's share price × the shares outstanding in its filings. Same measure as blue, but rougher.
Cap table
Share counts as of May 10, 2024| Class | Outstanding | Votes / share | Converts | As converted | Votes | Dividend | Last price |
|---|---|---|---|---|---|---|---|
| Series A Preferredpreferred | 5,000,000 | 1,000 | 1,000 × Common Stock | 97.6% | 97.8% | — | — |
| Series D Preferredpreferred | 250,236 | none | 60 × common stock | 0.29% | 0% | 8% | — |
| Series B Preferredpreferred | 99,500 | none | — | 0% | 0% | 8% | — |
| Common Stock | 109,649,538 | 1 | — | 2.14% | 2.15% | — | $0.15Jan 2022 |
| Total | 114,999,274 | 5,124,763,198 as converted | 100% | 100% |
Shares outstanding over timein today's share terms
Changes in named holdersshares in today's terms · % of all shares at the time
- MDHC Johnson Family Partnership18K (0.35%) Jan 2022 → 1.0M (18.2%) Feb 2023 → 236K (4.3%) Feb 2023 → 1.0M (18.2%) Feb 2023 → 104K (1.94%) Feb 2024
- Chase Zeman2.6M (15.0%) Feb 2016 → 2.4M (46.7%) Jan 2022
- Kirk Kimerer3.1M (17.7%) Feb 2016 → 1.7M (33.3%) Jan 2022
Principal holders% as the filing states it, May 10, 2024
- David Mersky, CEO, CFO, Secretary, Director5,000,000 Series A Preferred100.0%of Series A Preferred
- Eric Stoll80,000 Series B Preferred82.0%of company
- Eric Stoll - Chief Marketing Officer80,000 Series B Preferred82.0%of Series B Preferred
- Rubicon Peak Capital, LLC146,305 Series D Preferred58.0%of Series D Preferred
- MDHC Johnson Family Partnership103,930 Series D Preferred42.0%of Series D Preferred
- David Mersky, CEO, CFO, Secretary, Director31,666,667 Common29.0%of
- MDHC Johnson Family Partnership18,000 Series B Preferred18.0%of Series B Preferred
- MDHC Johnson Family Partnership1,000,000 Common0.9%of
- Everyone else (not named in filings)18.0%
Sold to the crowd
- Reg A+ · Jan 20221,963,335 Common Stock, $.001 par value at $0.15$294.5K
From the company's SEC filings: share counts per class, each class's voting and conversion terms, and the holders of 20% or more that Form C requires (officers and 10%+ holders on Form 1-A). Filings name only large holders, so most owners — including crowd investors — are not listed, and a holder's percentage may be of its own class rather than of the whole company. “As converted” counts each class in the shares it converts into. Prices and crowd share counts are in today's share terms — adjusted for splits and conversions since they were sold. Hover a figure for its filing.
Fundraising history
Team
3 peopleNames and titles as disclosed on SEC Form 1-A. Bios and photos come from the platform campaign page and may be out of date.
SEC filings
View all 37 filings on EDGAR- Form QUALIFMay 22, 20249999999994-24-000066EDGAR
- Form 1-A POSMay 10, 20240001683168-24-003183EDGAR
- Form 1-A POSApr 12, 20240001683168-24-002347EDGAR
- Form 1-A POSFeb 2, 20240001683168-24-000618EDGAR
- Form QUALIFMar 15, 20239999999994-23-000110EDGAR
- Form 1-A-WFeb 17, 20230001683168-23-001012EDGAR
- Form 1-A-WFeb 17, 20230001683168-23-001010EDGAR
- Form 1-AFeb 17, 20230001683168-23-001035EDGAR
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.